@article{5a91d197c5a4468c9af77bc1376f6d52,
title = "Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials",
author = "Langley, {R. G.} and Armstrong, {A. W.} and Lebwohl, {M. G.} and A. Blauvelt and S. Hsu and S. Tyring and S. Rastogi and R. Pillai and R. Israel",
note = "Funding Information: Conflicts of interest. R.G.L. has been a consultant, advisory board member and/or paid speaker for AbbVie, Inc.; Amgen; Boehringer Ingelheim; Celgene; Centocor; Eli Lilly; LEO; Novartis; Pfizer and Sun Pharma. A.W.A. has served as a consultant for AbbVie, Inc; Janssen; Eli Lilly; Novartis Pharmaceuticals Corporation and Pfizer, Inc. and has served as an investigator for AbbVie, Inc.; Janssen and Eli Lilly & Co and as a member of the speaker{\textquoteright}s bureau for AbbVie, Inc.; Eli Lilly and Janssen. M.G.L. is an employee of Mount Sinai, which receives research funds from AbbVie, Inc.; Amgen; Boehringer Ingelheim; Celgene; Eli Lilly; Janssen/Johnson & Johnson; Kadmon; Medimmune/AstraZe-neca; Novartis; Pfizer; Valeant and Vidac, and is also a consultant for Allergan, Aqua, LEO Pharma and Promius. A.B. has served as a scientific adviser and clinical study investigator for AbbVie, Inc.; Aclaris; Allergan; Almirall; Amgen; Boehringer Ingelheim; Celgene; Dermavant; Dermira; Eli Lilly; Genentech/Roche; GlaxoSmithKline; Janssen; LEO; Meiji; Merck Sharp & Dohme; Novartis; Pfizer; Purdue Pharma; Regeneron; Sandoz; Sanofi Genzyme; Sienna Pharmaceuticals; Sun Pharma; UCB; Valeant and Vidac, and as a paid speaker for Eli Lilly, Janssen, Regeneron and Sanofi Genzyme. S.H. has served as an investigator, consultant or advisory board member for Centocor Biotech; Abbott Laboratories; Eli Lilly; Genentech; Janssen Biotech; AbbVie, Inc.; Sun Pharma/Ranbaxy; Medicis Pharmaceutical; Galderma; Pro-mius Pharma; Dermik; Biogen; Amgen; Novartis; Regeneron; Sanofi and Valeant Pharmaceuticals North America LLC. S.T. has received payments and research funding from LEO Pharma. S.R. is an employee of Ortho Dermatologics and holds stocks and/or stock options in Valeant Pharmaceuticals. R.P. is an employee of Dow Pharmaceutical Sciences (a division of Valeant Pharmaceuticals North America LLC) and holds stock and/or stock options in the company. R.I. is an employee of Valeant Pharmaceuticals North America LLC and holds stock and/or stock options in the company. Funding Information: This study was supported by Ortho Dermatologics. Publisher Copyright: {\textcopyright} 2018 British Association of Dermatologists",
year = "2019",
month = feb,
doi = "10.1111/bjd.17318",
language = "English",
volume = "180",
pages = "306--314",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "2",
}